Japanese businesses wanting to develop techniques for the regeneration of human tissue and commercialize their products are facing a major obstacle.

While pharmaceutical companies envision their products helping countless people and generating enormous profits, the government is slow to react to the rapid advances in technology.

With the strict nature of current regulations, Japanese are unlikely to reap any benefits from the new technology -- at least not soon.